Indian mutual funds are investing Rs 1.07 lakh crore in 20 key stocks to counter historic FII selling. They are focusing on large-cap priva...

Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...

Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...

Mutual funds injected Rs 30,600 crore into Indian equities in April, with significant buying in ICICI Bank, SBI, and Sun Pharma. Key reduct...

Biocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...

Biocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges im...

Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...

Biocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolida...

Indian markets showed resilience, climbing despite volatility, buoyed by positive global trends and falling crude oil prices. Analysts anti...

Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...

Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...

US company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...

Biocon shares: The company also reported consolidated revenue of Rs 4,454 crore, reflecting a 15% year-on-year increase on a like-for-like ...

Sen was appointed as the CFO of the company in April 2021 after Anupam Jindal stepped down. He has over 20 years of experience in financial...

Indian biopharmaceutical company Biocon posted a 31% year-on-year rise in Q4 FY23 net profit, at INR313 crore ($41.9m), driven by successfu...

Biocon Ltd., incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 31515.75 Crore) operating in Pharmaceuticals ...

The consolidated revenue of Biocon was up by 11.38 per cent at Rs 861 crore during the quarter compared to Rs 773 crore in the year-ago per...